Developing novel neuroplastic therapeutics to treat central nervous system disorders
CNS drug discovery. CNS drug discovery. CNS drug discovery.
inspired by nature. powered by AI.
Promoting neuroplasticity.
We are a clinical stage biotech company. Our lead R&D program focuses on activating the Tropomyosin receptor kinase B (TrkB) receptor pathway, which promotes neuronal survival and synaptic plasticity. Our lead candidate OT-003 and fast follower OT-1xx series have generated compelling data in a variety of central nervou system disorders with significant unmet need.
Unlocking Neuroplasticity
57 Mn
... growing to over 150 Mn by 2050. There is an urgent need for new treatments addressing neurological and neuropsychiatric diseases.
25 Mn
... with one-third being treatment resistant.
80 Mn
... for which there is no cure.
65%
... do not fully recover by using antidepressant medication
Our lead asset OT-003 shows compelling efficacy across neurological disease models and we have received our Clinical Trial Authorization (CTA). We are also advancing our pipeline of next-generation TrkB activators. These show compelling pharmacology and possess a range of PK properties, enabling progression in distinct neurological disorders
We share news and trends around Pangea and our research space.
